Why is Viking Therapeutics stock surging today?

Viking Therapeutics' shares jumped 39.5% in pre-market trading following the release of impressive top-line results from its VK2735 maintenance study. The San Diego-based biopharmaceutical company showcased compelling data that addressed a major question in the GLP-1/GIP receptor agonist space: can patients maintain weight loss with reduced dosing frequencies?

In the 12-week maintenance phase, every-other-week dosing managed to preserve up to 97% of prior weight loss, while monthly dosing yielded up to 90% retention, compared to only 61% for placebo. This data provided strong evidence that VK2735 could potentially establish adherence as a new competitive battleground in obesity and chronic metabolic disease.

The encouraging safety profile of VK2735, with GI-related adverse events comparable to placebo, further bolstered investor confidence. The company plans to explore oral maintenance dosing regimens in a future part 2 of the study. Viking stock had already been on an upward trajectory ahead of the data release, with Oppenheimer maintaining an Outperform rating and a $100 price target. The positive news was driven entirely by company-specific results and not influenced by broader market trends.